Chief Legal Officer · Astria Therapeutics, Inc. (ATXS)

Benjamin Harshbarger

A named executive officer of Astria Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,447,933

FY2023: $1,297,491

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A).

Benjamin Harshbarger compensation by year

Astria Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Astria Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$439,635$461,617
Bonus$0$0
Stock awards$0$0
Option awards$660,020$1,789,892
Non-equity incentive$195,638$184,647
Pension and deferred compensation$0$0
All other$2,198$11,777
Total$1,297,491$2,447,933

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Astria Therapeutics, Inc. DEF 14A filed April 28, 2025, accession 0001104659-25-040180, and prior-year filings. Open the filing on EDGAR.

$1.3M
$2.4M
FY23
FY24
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option48,750—$13.36
Option5,556—$17.22
Option4,164—$12.96
Option16,042—$6.51
Option175,000—$15.26

Per the Outstanding Equity Awards at Fiscal Year-End table in Astria Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments Astria Therapeutics discloses, by trigger · FY2024
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$461,617$0$29,868$491,485
Resignation for good reason, no change in control$461,617$0$29,868$491,485
Change in control and involuntary termination$461,617$38,982$29,868$530,467

Per the Potential Payments Upon Termination or Change in Control table in Astria Therapeutics, Inc.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.

Astria Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Jill MilnePresident and Chief Executive Officer$6,604,416
Christopher MorabitoChief Medical Officer$2,480,716
Benjamin Harshbarger · this pageChief Legal Officer$2,447,933

The full Astria Therapeutics compensation record

free company brief

This page is one person within Astria Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Astria Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Astria Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy